A cost-utility analysis comparing two sequences of treatment for first-line chemotherapy in metastatic prostate cancer (MCRPC): Cabazitaxel followed by docetaxel versus docetaxel followed by cabazitaxel

This article has no abstract
Epistemonikos ID: ce565d6485563220db6c74209f3543d93c1726ab
First added on: Feb 08, 2025